AU2019415299A1 - Composition for improving cognitive function - Google Patents

Composition for improving cognitive function Download PDF

Info

Publication number
AU2019415299A1
AU2019415299A1 AU2019415299A AU2019415299A AU2019415299A1 AU 2019415299 A1 AU2019415299 A1 AU 2019415299A1 AU 2019415299 A AU2019415299 A AU 2019415299A AU 2019415299 A AU2019415299 A AU 2019415299A AU 2019415299 A1 AU2019415299 A1 AU 2019415299A1
Authority
AU
Australia
Prior art keywords
cla
tll
cognitive function
composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019415299A
Other languages
English (en)
Inventor
Saori BAN
Hiroto Komano
Shunji Natori
Toshiharu Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Demencare Laboratory Inc
Original Assignee
Demencare Laboratory Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Demencare Laboratory Inc filed Critical Demencare Laboratory Inc
Publication of AU2019415299A1 publication Critical patent/AU2019415299A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Polymers & Plastics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019415299A 2018-12-25 2019-12-25 Composition for improving cognitive function Abandoned AU2019415299A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018241320 2018-12-25
JP2018-241320 2018-12-25
PCT/JP2019/051030 WO2020138244A1 (ja) 2018-12-25 2019-12-25 認知機能改善用の組成物

Publications (1)

Publication Number Publication Date
AU2019415299A1 true AU2019415299A1 (en) 2021-08-12

Family

ID=71129556

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019415299A Abandoned AU2019415299A1 (en) 2018-12-25 2019-12-25 Composition for improving cognitive function

Country Status (5)

Country Link
US (1) US20220096415A1 (enExample)
EP (1) EP3903776A4 (enExample)
JP (1) JPWO2020138244A1 (enExample)
AU (1) AU2019415299A1 (enExample)
WO (1) WO2020138244A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009088939A2 (en) * 2008-01-02 2009-07-16 Marine Bio Co., Ltd. Compositions and methods for treating neurodegenerative diseases
CN101524346A (zh) * 2009-04-08 2009-09-09 中山大学 共轭亚油酸在制备治疗阿尔茨海默病药物中的应用
WO2017223049A1 (en) * 2016-06-23 2017-12-28 Stepan Specialty Products, Llc Compositions comprising rumenic acid-rich conjugated linoleic acid for brain health
JP6968564B2 (ja) * 2017-04-04 2021-11-17 俊二 名取 共役リノール酸組成物及びその製造方法

Also Published As

Publication number Publication date
WO2020138244A1 (ja) 2020-07-02
EP3903776A4 (en) 2022-10-05
JPWO2020138244A1 (enExample) 2020-07-02
US20220096415A1 (en) 2022-03-31
EP3903776A1 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
RU2444356C2 (ru) Полиненасыщенные жирные кислоты для лечения деменции и состояний, связанных с преддеменцией
Che et al. EPA-enriched ethanolamine plasmalogen and EPA-enriched phosphatidylethanolamine enhance BDNF/TrkB/CREB signaling and inhibit neuronal apoptosis in vitro and in vivo
Kelley et al. Conjugated linoleic acid isomers and cancer
Monastra et al. Alpha-lactalbumin effect on myo-inositol intestinal absorption: in vivo and in vitro
JP5847086B2 (ja) 抗中枢神経系炎症剤
US8324276B2 (en) Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
US20190314425A1 (en) Akkermansia muciniphila strain having a prophylactic or therapeutic effect on a degenerative brain disease or metabolic disease and use thereof
KR101253696B1 (ko) 아밀로이드-관련 질환의 치료용 의약품 또는 식품의 생산을 위한 ｄｈａ 함유 지방산 조성물의 용도
JP6942061B2 (ja) 動物脳抽出物を調製するためのプロセス
KR20230004545A (ko) Lpc-dha 및 lpc-epa가 풍부한 크릴 오일 조성물
JP7850416B2 (ja) 細胞外小胞に含まれるｅｎａｍｐｔの産生および使用
JP2022538212A (ja) 疾患の治療および軽減のための超長鎖脂肪酸
US9603869B2 (en) Lithium co-crystals and an additional neuropsychiatric agent for treatment of neuropsychiatric disorders
CN110691599A (zh) 使用脂多糖的脑功能改善剂、食品和药品
ES2936725T3 (es) Composición para el tratamiento y/o prevención de la enfermedad de Alzheimer
CN110292571A (zh) 姜黄素衍生物的用途
KR20150063006A (ko) 난각막 성분을 포함한 인슐린 저항성 개선제 및 그것을 이용한 조성물
EP3903776A1 (en) Composition for improving cognitive function
JP2010222284A (ja) 血中ｇｉｐ上昇抑制剤
JP5769912B2 (ja) 認知障害を伴う疾患又は状態の予防又は治療用の組成物
TW201725035A (zh) 用於治療及預防神經疾病、神經炎症及阿茲海默氏症之組合物
JPWO2010058517A1 (ja) ＩｇＧおよび／またはＩｇＧのＦｃ断片を含む神経細胞刺激剤
US20220249420A1 (en) Monounsaturated fatty acid composition and use for treating fatty liver disease
JP2011509257A (ja) 神経変性疾患を処置するための組成物および方法
KR102374047B1 (ko) N,N′-디아세틸-p-페닐렌디아민 화합물을 유효성분으로 포함하는 알츠하이머병 예방, 개선 또는 치료용 조성물

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period